Heart Failure – AstraZeneca D6402C00012

Profound Research and Michigan Healthcare Professionals are enrolling a study that is assessing an investigational medication to see if it reduces the risk of a heart failure event in adults with heart failure and impaired kidney function.

To be eligible to participate, you must:

• Be ages 18+
• Have had a recent heart failure event defined as:
  • Hospitalization within the last 6 months
  • Currently hospitalized due to worsening of chronic heart failure
• Have chronic kidney impairment
• Have an ejection fraction assessment within the last 12 months or be willing to undergo an echocardiogram at the screening visit
• Be taking medications for heart failure AND impaired kidney function (MRA medications are prohibited – these include spironolactone, eplerenone, finerenone)
• Have an NT-proBNP > 300

Additional criteria apply.

Qualified participants will receive:

Study-related care and study medication at no cost; Study medication includes dapagliflozin (Farxiga)
Financial reimbursement for time and travel expenses